Tepotinib
MS200095-0022
Phase 2 small_molecule active
Quick answer
Tepotinib for Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification is a Phase 2 program (small_molecule) at Serono Europe Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Serono Europe Limited
- Indication
- Advanced (Stage IIIB/IV) Non-small Cell Lung Cancer (NSCLC) With MET Exon 14 (METex14) Skipping Alterations or MET Amplification
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active